Delaware | 1-16671 | 23-3079390 | ||
(State or other jurisdiction of | (Commission File Number) | (IRS Employer | ||
incorporation) | Identification No.) | |||
1300 Morris Drive | ||||
Chesterbrook, PA 19087 | ||||
(Address of principal executive offices, including Zip Code) |
Exhibit Number | Description of Exhibit | |
99.1 |
AMERISOURCEBERGEN CORPORATION | |||
Date: | February 6, 2018 | By: | /s/ Tim G. Guttman |
Name: | Tim G. Guttman | ||
Title: | Executive Vice President & Chief Financial Officer |
![]() | |
![]() | AmerisourceBergen Corporation |
P.O. Box 959 | |
Valley Forge, PA 19482 |
GAAP | Adjusted (Non-GAAP) | |
Revenue | $40.5B | $40.5B |
Gross Profit | $1.1B | $1.1B |
Operating Expenses | $694M | $625M |
Operating Income | $419M | $488M |
Interest Expense, Net | $36M | $36M |
Tax Rate | (140.1)% | 24.2% |
Net Income | $862M | $342M |
Diluted Shares Outstanding | 221M | 221M |
Diluted Earnings Per Share | $3.90 | $1.55 |
• | Revenue: In the first quarter of fiscal 2018, revenue was $40.5 billion, up 6.0 percent compared to the same quarter in the previous fiscal year, reflecting a 5.8 percent increase in Pharmaceutical Distribution Services revenue and an 11.6 percent increase in revenue within Other. |
• | Gross Profit: Gross profit in the fiscal 2018 first quarter was $1.1 billion, a 7.2 percent increase over the same period in the previous fiscal year, primarily due to the increase in gross profit in Pharmaceutical Distribution Services and the decrease in LIFO expense of $28.3 million. Gross profit as a percentage of revenue was 2.75%, an increase of 3 basis points from the prior year quarter. |
• | Operating Expenses: In the first quarter of fiscal 2018, operating expenses were $693.7 million, compared to $637.7 million in the same period last fiscal year. The increase in operating expenses was primarily driven by operating additional distribution centers in the current quarter and duplicate costs resulting from the implementation of new information technology systems, as well as increased costs to support our revenue growth. |
• | Operating Income: In the fiscal 2018 first quarter, operating income was $419.0 million versus $400.0 million in the prior year period. |
• | Interest Expense, Net: In the fiscal 2018 first quarter, net interest expense of $35.9 million was down 3.0 percent versus the prior year quarter. |
• | Tax Rate: The effective tax rate of (140.1)% for the first quarter of fiscal 2018 benefited from $587.6 million of discrete tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from U.S. tax reform. |
• | Diluted Earnings Per Share: Diluted earnings per share was $3.90 in the first quarter of fiscal year 2018 compared to $1.11 in the previous fiscal year’s first quarter, primarily driven by the benefit from U.S. tax reform. |
• | Diluted Shares Outstanding: Diluted weighted average shares outstanding for the first quarter of fiscal year 2018 were 220.8 million, a 0.5 percent decline versus the prior fiscal year first quarter due primarily to share repurchases, net of stock option exercises. |
• | Warrants expense; |
• | Gain from antitrust litigation settlements; |
• | LIFO expense; |
• | Acquisition-related intangibles amortization; |
• | Employee severance, litigation, and other; |
• | Loss on early retirement of debt; and a |
• | One-time tax reform adjustment. |
• | Revenue: In the first quarter of fiscal 2018, revenue was $40.5 billion, up 6.0 percent compared to the same quarter in the previous fiscal year, reflecting a 5.8 percent increase in Pharmaceutical Distribution Services revenue and an 11.6 percent increase in revenue within Other. |
• | Adjusted Gross Profit: Gross profit in the fiscal 2018 first quarter was $1.1 billion, which was up 4.5 percent when compared to the same period in the previous year, primarily due to the increase in gross profit in Pharmaceutical Distribution Services. Gross profit as a percentage of revenue was 2.75 percent, a decrease of 4 basis points from the prior year quarter. |
• | Adjusted Operating Expenses: In the first quarter of fiscal 2018, operating expenses were $624.6 million, an increase of 8.0% compared to the same period in the last fiscal year. Operating expenses as a percentage of revenue in the fiscal 2018 first quarter were 1.54 percent, compared to 1.52 percent for the same period in the previous fiscal year. The increase in operating expenses was primarily driven by operating additional distribution centers in the current quarter and duplicate costs resulting from the implementation of new information technology systems, as well as increased costs to support our revenue growth. |
• | Adjusted Operating Income: In the fiscal 2018 first quarter, operating income of $488.1 million increased 0.4 percent from the prior year period. Operating income as a percentage of revenue decreased 6 basis points to 1.21 percent in the fiscal 2018 first quarter compared to the previous fiscal year’s first quarter. |
• | Adjusted Interest Expense, Net: In the fiscal 2018 first quarter, net interest expense of $35.9 million was up 3.0 percent from the prior year quarter. |
• | Adjusted Tax Rate: The effective tax rate for the first quarter of fiscal 2018 was 24.2 percent, down from 33.1 percent in the previous fiscal year’s first quarter, primarily driven by a reduction in the U.S. federal income tax rate from 35% to 21%, as a result of U.S. tax reform. |
• | Adjusted Diluted Earnings Per Share: Diluted earnings per share was up 14.0 percent to $1.55 in the first quarter of fiscal year 2018 compared to $1.36 in the previous fiscal year’s first quarter, driven primarily by a $0.15 benefit from U.S. tax reform. |
• | Diluted Shares Outstanding: Diluted weighted average shares outstanding for the first quarter of fiscal year 2018 were 220.8 million, a 0.5 percent decline versus the prior fiscal year first quarter due primarily to share repurchases, net of stock option exercises. |
• | Completed the acquisition of H. D. Smith, the largest independent pharmaceutical wholesaler in the U.S., which enhances and expands our strategic scale, strengthens our support to community pharmacy and drives long-term, durable value. |
• | Recorded our 16th consecutive quarter with 10 percent or greater revenue growth in Specialty distribution. |
• | Now servicing more than 600 retail pharmacies acquired by Walgreens Boots Alliance through its phased acquisition of certain Rite Aid stores. |
• | Opened a 6th new distribution center in Newburgh, NY with state-of-the-art automation as part of our commitment to creating the most efficient healthcare and pharmaceutical network. |
• | Good Neighbor Pharmacy, AmerisourceBergen's independent pharmacy network, was ranked “Highest in Customer Satisfaction with Chain Drug Store Pharmacies” in the J.D. Power 2017 U.S. Pharmacy Study. |
• | World Courier had a record-setting quarter in both shipments and billable weight. Additionally, the business achieved Good Distribution Practice certification across its global network of 140-plus offices. |
• | MWI acquired Northeast Veterinary Supply Co., an independent, regional distributor of veterinary pharmaceuticals and medical supplies servicing primarily the northeast region of the U.S. |
• | The Lash Group successfully migrated its first customers onto its innovative Fusion technology ecosystem with positive user feedback. Fusion was also featured in The Center Watch Monthly's 2018 Top Innovators. This onboarding process is advancing, but at a slower pace than originally anticipated. |
• | The AmerisourceBergen Foundation launched a municipal support program that aims to promote the safe disposal of opioids by providing communities nationwide with resources to deactivate expired or unused prescription medications. |
• | US Bioservices, AmerisourceBergen's independent specialty pharmacy, had a record breaking year for new business wins in 2017, further expanding its portfolio of critical specialty therapies. |
• | Revenue growth in the range of 8 percent to 11 percent; and |
• | Adjusted diluted earnings per share now to be in the range of $6.45 to $6.65. |
• | Adjusted operating expenses to increase between 6 percent to 8 percent; |
• | Adjusted operating income growth in the range of 1 percent to 4 percent; |
• | Pharmaceutical Distribution Services segment operating income growth in the range of 1 percent to 4 percent; |
• | Other, which is comprised of businesses focused on Global Commercialization Services and Animal Health, operating income growth in the range of flat to 2 percent; |
• | Adjusted effective tax rate of between 23 percent and 24 percent; |
• | Adjusted free cash flow to be approximately $1.35 billion to $1.6 billion; |
• | Capital expenditures of approximately $325 million; and |
• | Share repurchases will offset dilution from employee stock option exercises. |
• | Brand drug inflation to be in the range of 6 percent to 7 percent; |
• | Generic drug deflation to be in the range of -7 percent to -9 percent; |
• | Contributions from new generic launches similar to the prior year; and |
• | No significant contributions from biosimilars. |
Three Months Ended December 31, 2017 | % of Revenue | Three Months Ended December 31, 2016 | % of Revenue | % Change | ||||||||||
Revenue | $ | 40,466,332 | $ | 38,169,265 | 6.0% | |||||||||
Cost of goods sold | 39,353,680 | 37,131,585 | 6.0% | |||||||||||
Gross profit 1 | 1,112,652 | 2.75% | 1,037,680 | 2.72% | 7.2% | |||||||||
Operating expenses: | ||||||||||||||
Distribution, selling, and administrative | 558,522 | 1.38% | 520,547 | 1.36% | 7.3% | |||||||||
Depreciation and amortization | 105,136 | 0.26% | 96,080 | 0.25% | 9.4% | |||||||||
Employee severance, litigation, and other 2 | 30,021 | 21,066 | ||||||||||||
Total operating expenses | 693,679 | 1.71% | 637,693 | 1.67% | 8.8% | |||||||||
Operating income | 418,973 | 1.04% | 399,987 | 1.05% | 4.7% | |||||||||
Other loss (income) | 324 | (123 | ) | |||||||||||
Interest expense, net | 35,864 | 36,972 | (3.0)% | |||||||||||
Loss on early retirement of debt | 23,766 | — | ||||||||||||
Income before income taxes | 359,019 | 0.89% | 363,138 | 0.95% | (1.1)% | |||||||||
Income tax (benefit) expense | (502,834 | ) | 115,892 | |||||||||||
Net income | $ | 861,853 | 2.13% | $ | 247,246 | 0.65% | 248.6% | |||||||
Earnings per share: | ||||||||||||||
Basic | $ | 3.95 | $ | 1.13 | 249.6% | |||||||||
Diluted | $ | 3.90 | $ | 1.11 | 251.4% | |||||||||
Weighted average common shares outstanding: | ||||||||||||||
Basic | 218,323 | 218,661 | (0.2)% | |||||||||||
Diluted | 220,822 | 221,979 | (0.5)% |
1 | Includes $28.3 million LIFO expense and $1.4 million gain from antitrust litigation settlements in the three months ended December 31, 2016. |
2 | Includes $23.1 million of employee severance and other costs, $4.1 million of deal-related transaction costs, and $2.8 million of litigation costs in the three months ended December 31, 2017. Other costs in the three months ended December 31, 2017 include $8.3 million of certain fixed costs and scrapped non-usable inventory related to one of the Company's 503B outsourcing facilities, which voluntarily suspended production in December 2017 pending execution of certain remedial measures. Includes $4.5 million of employee severance and other costs, a $16.0 million litigation settlement, and $0.5 million of deal-related transaction costs in the three months ended December 31, 2016. |
Three Months Ended December 31, 2017 | ||||||||||||||||||||||||||||||||||||
Gross Profit | Operating Expenses | Operating Income | Interest Expense, Net | Loss on Early Retirement of Debt | Income Before Income Taxes | Income Tax (Benefit) Expense | Net Income | Diluted Earnings Per Share | ||||||||||||||||||||||||||||
GAAP | $ | 1,112,652 | $ | 693,679 | $ | 418,973 | $ | 35,864 | $ | 23,766 | $ | 359,019 | $ | (502,834 | ) | $ | 861,853 | $ | 3.90 | |||||||||||||||||
Acquisition-related intangibles amortization | — | (39,056 | ) | 39,056 | — | — | 39,151 | 10,435 | 28,716 | 0.13 | ||||||||||||||||||||||||||
Employee severance, litigation, and other | — | (30,021 | ) | 30,021 | — | — | 30,021 | 8,001 | 22,020 | 0.10 | ||||||||||||||||||||||||||
Loss on early retirement of debt | — | — | — | — | (23,766 | ) | 23,766 | 6,334 | 17,432 | 0.08 | ||||||||||||||||||||||||||
Tax reform 1 | — | — | — | — | — | — | 587,595 | (587,595 | ) | (2.66 | ) | |||||||||||||||||||||||||
Adjusted Non-GAAP | $ | 1,112,652 | $ | 624,602 | $ | 488,050 | $ | 35,864 | $ | — | $ | 451,957 | $ | 109,531 | $ | 342,426 | $ | 1.55 | ||||||||||||||||||
Adjusted Non-GAAP % changes vs. prior year quarter | 4.5% | 8.0% | 0.4% | 3.0% | —% | 0.1% | (26.8)% | 13.4% | 14.0% |
Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
Gross profit | 2.75% | 2.75% | ||
Operating expenses | 1.71% | 1.54% | ||
Operating income | 1.04% | 1.21% |
1 | Includes the impact of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017, offset in part by a one-time transition tax on historical foreign earnings and profits through December 31, 2017. |
Three Months Ended December 31, 2016 | |||||||||||||||||||||||||||||||||
Gross Profit | Operating Expenses | Operating Income | Interest Expense, Net | Income Before Income Taxes | Income Tax Expense | Net Income | Diluted Earnings Per Share | ||||||||||||||||||||||||||
GAAP | $ | 1,037,680 | $ | 637,693 | $ | 399,987 | $ | 36,972 | $ | 363,138 | $ | 115,892 | $ | 247,246 | $ | 1.11 | |||||||||||||||||
Warrants expense 1 | — | — | — | (2,155 | ) | 2,155 | 821 | 1,334 | 0.01 | ||||||||||||||||||||||||
Gain from antitrust litigation settlements | (1,395 | ) | — | (1,395 | ) | — | (1,395 | ) | (531 | ) | (864 | ) | — | ||||||||||||||||||||
LIFO expense | 28,308 | — | 28,308 | — | 28,308 | 10,776 | 17,532 | 0.08 | |||||||||||||||||||||||||
Acquisition-related intangibles amortization | — | (38,229 | ) | 38,229 | — | 38,322 | 14,588 | 23,734 | 0.11 | ||||||||||||||||||||||||
Employee severance, litigation, and other | — | (21,066 | ) | 21,066 | — | 21,066 | 8,020 | 13,046 | 0.06 | ||||||||||||||||||||||||
Adjusted Non-GAAP | $ | 1,064,593 | $ | 578,398 | $ | 486,195 | $ | 34,817 | $ | 451,594 | $ | 149,566 | $ | 302,028 | $ | 1.36 | 2 |
Percentages of Revenue: | GAAP | Adjusted Non-GAAP | ||
Gross profit | 2.72% | 2.79% | ||
Operating expenses | 1.67% | 1.52% | ||
Operating income | 1.05% | 1.27% |
1 | In connection with the fiscal 2014 special $650 million share repurchase program, which was established to mitigate the dilutive effect of the Warrants, the Company issued $600 million of 1.15% senior notes that were repaid in May 2017. The interest expense incurred relating to this borrowing has been excluded from the non-GAAP presentation. |
2 | The sum of the components does not equal the total due to rounding. |
Three Months Ended December 31, | ||||||||||
Revenue | 2017 | 2016 | % Change | |||||||
Pharmaceutical Distribution Services | $ | 38,937,698 | $ | 36,798,289 | 5.8% | |||||
Other | 1,544,951 | 1,384,490 | 11.6% | |||||||
Intersegment eliminations | (16,317 | ) | (13,514 | ) | ||||||
Revenue | $ | 40,466,332 | $ | 38,169,265 | 6.0% |
Three Months Ended December 31, | ||||||||||
Operating income | 2017 | 2016 | % Change | |||||||
Pharmaceutical Distribution Services | $ | 388,182 | $ | 379,060 | 2.4% | |||||
Other | 100,275 | 107,148 | (6.4)% | |||||||
Intersegment eliminations | (407 | ) | (13 | ) | ||||||
Total segment operating income | 488,050 | 486,195 | 0.4% | |||||||
Gain from antitrust litigation settlements | — | 1,395 | ||||||||
LIFO expense | — | (28,308 | ) | |||||||
Acquisition-related intangibles amortization | (39,056 | ) | (38,229 | ) | ||||||
Employee severance, litigation, and other | (30,021 | ) | (21,066 | ) | ||||||
Operating income | $ | 418,973 | $ | 399,987 | ||||||
Percentages of revenue: | ||||||||||
Pharmaceutical Distribution Services | ||||||||||
Gross profit | 2.04% | 2.05% | ||||||||
Operating expenses | 1.04% | 1.02% | ||||||||
Operating income | 1.00% | 1.03% | ||||||||
Other | ||||||||||
Gross profit | 20.75% | 22.36% | ||||||||
Operating expenses | 14.26% | 14.63% | ||||||||
Operating income | 6.49% | 7.74% | ||||||||
AmerisourceBergen Corporation (GAAP) | ||||||||||
Gross profit | 2.75% | 2.72% | ||||||||
Operating expenses | 1.71% | 1.67% | ||||||||
Operating income | 1.04% | 1.05% | ||||||||
AmerisourceBergen Corporation (Non-GAAP) | ||||||||||
Adjusted gross profit | 2.75% | 2.79% | ||||||||
Adjusted operating expenses | 1.54% | 1.52% | ||||||||
Adjusted operating income | 1.21% | 1.27% |
December 31, | September 30, | ||||||
2017 | 2017 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 3,037,747 | $ | 2,435,115 | |||
Accounts receivable, net | 10,127,783 | 10,303,324 | |||||
Merchandise inventories | 12,020,660 | 11,461,428 | |||||
Prepaid expenses and other | 110,242 | 103,432 | |||||
Total current assets | 25,296,432 | 24,303,299 | |||||
Property and equipment, net | 1,829,117 | 1,797,945 | |||||
Goodwill and other intangible assets | 8,901,145 | 8,877,562 | |||||
Other long-term assets | 334,816 | 337,664 | |||||
Total assets | $ | 36,361,510 | $ | 35,316,470 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 25,346,694 | $ | 25,404,042 | |||
Other current liabilities | 1,393,597 | 1,414,123 | |||||
Total current liabilities | 26,740,291 | 26,818,165 | |||||
Long-term debt | 4,266,757 | 3,429,934 | |||||
Accrued income taxes | 391,107 | 84,257 | |||||
Deferred income taxes | 1,659,619 | 2,492,612 | |||||
Other long-term liabilities | 429,154 | 427,041 | |||||
Stockholders’ equity | 2,874,582 | 2,064,461 | |||||
Total liabilities and stockholders’ equity | $ | 36,361,510 | $ | 35,316,470 |
Three Months Ended December 31, | |||||||
2017 | 2016 | ||||||
Operating Activities: | |||||||
Net income | $ | 861,853 | $ | 247,246 | |||
Adjustments to reconcile net income to net cash provided by (used in) operating activities 1, 2 | (675,558 | ) | 200,402 | ||||
Changes in operating assets and liabilities, excluding the effects of acquisitions: | |||||||
Accounts receivable | 91,624 | (536,937 | ) | ||||
Merchandise inventories | (460,127 | ) | (713,553 | ) | |||
Accounts payable | (59,223 | ) | 247,814 | ||||
Other 3 | 251,757 | 124,673 | |||||
Net cash provided by (used in) operating activities | 10,326 | (430,355 | ) | ||||
Investing Activities: | |||||||
Capital expenditures | (73,641 | ) | (137,282 | ) | |||
Cost of acquired companies, net of cash acquired | (70,330 | ) | (1,497 | ) | |||
Net purchases of investments in available-for-sale securities | — | (19,958 | ) | ||||
Other | 1,648 | 1,880 | |||||
Net cash used in investing activities | (142,323 | ) | (156,857 | ) | |||
Financing Activities: | |||||||
Net borrowings (repayments) 4 | 844,193 | (52,129 | ) | ||||
Purchases of common stock | (22,496 | ) | (229,928 | ) | |||
Payment of premium on early retirement of debt | (22,348 | ) | — | ||||
Exercises of stock options | 29,574 | 10,229 | |||||
Cash dividends on common stock | (83,555 | ) | (80,169 | ) | |||
Other | (10,739 | ) | (11,489 | ) | |||
Net cash provided by (used in) financing activities | 734,629 | (363,486 | ) | ||||
Increase (decrease) in cash and cash equivalents | 602,632 | (950,698 | ) | ||||
Cash and cash equivalents at beginning of period | 2,435,115 | 2,741,832 | |||||
Cash and cash equivalents at end of period | $ | 3,037,747 | $ | 1,791,134 |
1 | Adjustments include LIFO expense of $28.3 million for the three months ended December 31, 2016. |
2 | Includes an $840.5 million benefit for deferred income taxes for the three months ended December 31, 2017, primarily as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 in connection with tax reform. |
• | Adjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the gain from antitrust litigation settlements and LIFO expense because the Company cannot control the amounts recognized or timing of these items. Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. Management believes that these non-GAAP financial measures are useful to investors as a supplemental measure of the Company’s ongoing operating performance. The gain from antitrust litigation settlements relates to the settlement of class action lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. LIFO expense is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences. |
• | Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial measure that excludes acquisition-related intangibles amortization and employee severance, litigation, and other. Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. The acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of the acquired companies. We exclude employee severance amounts that relate to non-recurring organizational restructuring. We exclude the amount of litigation settlements and other expenses that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational performance. |
• | Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted operating expenses. Adjusted operating income margin is the ratio of adjusted operating income to total revenue. Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the Company’s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature. |
• | Adjusted interest expense, net: Adjusted interest expense is a non-GAAP financial measure that excludes the interest expense on our $600 million of 1.15% senior notes that were repaid in May 2017 (the “2017 Notes”). The 2017 Notes were issued to fund a special $650 million share repurchase program under which we purchased shares to reduce the dilution related to the warrants that we issued in March 2013 to wholly-owned subsidiaries of Walgreens Boots Alliance, Inc. Management believes that this non-GAAP financial measure is useful to investors in evaluating the Company’s ongoing interest expense, net. |
• | Adjusted tax rate: Adjusted tax rate is a non-GAAP financial measure that is determined by dividing adjusted income tax expense/benefit by adjusted income before income taxes. |
• | Adjusted net income: Adjusted net income is a non-GAAP financial measure that excludes the same items that are described above and excluded from adjusted gross profit, adjusted operating expenses, adjusted operating income, and adjusted interest expense, net. In addition, the loss on the early retirement of debt and the one-time impact of U.S. tax reform ("Tax Reform") are excluded from adjusted net income. Tax Reform includes a benefit from applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017, offset in part by a one-time transition tax on historical foreign earnings and profits through December 31, 2017. Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature. |
• | Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments including gain from antitrust litigation settlements; LIFO expense; acquisition-related intangibles amortization; employee severance, litigation, and other; the interest expense incurred in connection with the 2017 Notes; and the loss on early retirement of debt; in each case net of the tax effect calculated using the applicable effective tax rate for those items. In addition, the per share impact of Tax Reform is excluded from adjusted diluted earnings per share. Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature. |